journal article·2026-04Open access

Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosis

Jing Wang, Li Peng, Xinxin Zhong, Siqi Zheng, Xiuhua Liang, Menghan Du, Xiangning Xia, Ting Guo, Lidan Zheng, Yingying Fang, Yinghong Tian, Yusheng Shi, Xingmei Zhang

Abstract

Glioblastoma (GBM) is the highly lethal intracranial tumor characterized by low survival rates and high recurrence, partly attributable to the challenges posed by the blood-brain barrier (BBB). To enhance therapeutic efficacy, the Exo-U2-Dox complex was engineered by functionalizing mesenchymal stem cell (MSC)-derived exosomes with the GBM-targeting aptamer U2 and integrating them with doxorubicin (DOX). This complex is designed to augment the sensitivity of GBM to chemo-radiotherapy. Here, it is found that Exo-U2 effectively accumulates in GBM-bearing mice, thereby inhibiting tumor progression. When administered in conjunction with DOX and radiation, Exo-U2-Dox increases DNA damage in GBM cells, and diminishes invasiveness. Mechanistically, Exo-U2 targets and inhibits the autophosphorylation of Epidermal growth factor receptor variant Ш (EGFRvIII) in GBM cells, thereby activating the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome-mediated pyroptosis pathway, which leads to increased expression of Gasdermin D (GSDMD) and Cysteine-aspartic acid protease-1 (caspase-1), ultimately suppressing GBM cell proliferation, migration, and invasion. Furthermore, the combination of Exo-U2 with X-ray treatment inhibits the expression of p53-binding protein 1 (53BP1), reduces phosphorylation of the Ataxia-Telangiectasia Mutated/Checkpoint kinase 2 (ATM/Chk2) pathway, resulting in the accumulation of DNA damage. Collectively, these findings underscore the potential of aptamer-functionalized exosomes in conjunction with DOX as a promising strategy for GBM treatment. This approach not only broadens the therapeutic applications of DOX but also provides a novel direction for targeted GBM therapies. • The Exo-U2 complex demonstrates efficient blood-brain barrier penetration capabilities, enabling targeted accumulation at tumor sites. • The Exo-U2 complex significantly suppresses proliferation, migration, and invasion of gliblastoma in both in vitro and in vivo models. • The Exo-U2 complex triggers pyroptosis in U87EGFRvIII gliblastoma cells via the NLRP3-caspase-1-GSDMD signaling axis. • The Exo-U2-Dox complex notably enhances chemo-radiosensitivity, indicating its potential utility as a novel radiosensitizer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Extracellular vesicles in disease · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (52)

Show source-provided references
1. Dedifferentiated cells obtained from glioblastoma cell lines are an easy and robust model for mesenchymal glioblastoma stem cells studies
2. Brain and other central nervous system tumor statistics, 2021
3. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies10.1186/s12943-025-02267-0 ↗
4. Understanding and exploiting cell signalling convergence nodes and pathway cross-talk in malignant brain cancer10.1016/j.cellsig.2019.01.011 ↗
5. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response10.1038/nature05236 ↗
6. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance10.1158/0008-5472.CAN-11-1245 ↗
7. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma10.1038/s41591-025-03512-1 ↗
8. Cancer stem cell hypothesis 2.0 in glioblastoma: where are we now and where are we going?10.1093/neuonc/noae011 ↗
9. Engineered bacterial outer membrane vesicles-based doxorubicin and CD47-siRNA Co-Delivery nanoplatform overcomes immune resistance to potentiate the immunotherapy of glioblastoma
10. Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment10.1016/j.jconrel.2024.10.037 ↗
11. Potent therapeutic efficacy of intranasally deliverable paclitaxel modified with pH-sensitive and PEGylated polymeric micelle against glioblastoma10.1016/j.jconrel.2025.113711 ↗
12. Convection-enhanced delivery of auristatin-conjugated layer-by-layer nanoparticles for glioblastoma treatment10.1021/jacs.4c16898 ↗
13. Emerging role of exosomes in cancer therapy: progress and challenges10.1186/s12943-024-02215-4 ↗
14. Mesenchymal stem cell-derived exosomes ameliorate cardiomyocyte apoptosis in hypoxic conditions through microRNA144 by targeting the PTEN/AKT pathway10.1186/s13287-020-1563-8 ↗
15. Exosomal delivery of rapamycin modulates blood-brain barrier penetration and VEGF axis in glioblastoma10.1016/j.jconrel.2025.113605 ↗
16. Aptamers as targeted therapeutics: current potential and challenges10.1038/nrd.2016.199 ↗
17. Recent progress of aptamer-drug conjugates in cancer therapy10.1016/j.apsb.2023.01.017 ↗
18. Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer10.1186/s12951-025-03184-6 ↗
19. Effects of aptamer to U87-EGFRvIII cells on the proliferation, radiosensitivity, and radiotherapy of glioblastoma cells10.1016/j.omtn.2018.01.001 ↗
20. Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma10.2147/IJN.S238206 ↗
21. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-Intact glioblastoma cells10.1158/0008-5472.CAN-04-4392 ↗
22. microRNA-378 promotes mesenchymal stem cell survival and vascularization under hypoxic-ischemic conditions in vitro10.1186/scrt520 ↗
23. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy10.1016/j.biomaterials.2021.120784 ↗
24. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone10.1038/nprot.2009.238 ↗
25. Exosomes based strategies for brain drug delivery10.1016/j.biomaterials.2022.121949 ↗
26. Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives10.1002/anie.202003563 ↗
27. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death10.1038/nature15514 ↗
28. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases10.1111/imr.12534 ↗
29. Blood-brain barrier in brain tumors: biology and clinical relevance10.3390/ijms222312654 ↗
30. Exosomes: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake10.1016/j.jconrel.2022.05.027 ↗
31. Exosomes as immunotheranostic nanoparticles10.1016/j.clinthera.2014.04.019 ↗
32. Unravelling the therapeutic properties of aptamer-modified exosome nanocomposite10.1016/j.cis.2025.103517 ↗
33. Assembly and in vitro assessment of a powerful combination: aptamer-modified exosomes combined with gold nanorods for effective photothermal therapy10.1088/1361-6528/abb0b8 ↗
34. Microenvironment-driven bioelimination of magnetoplasmonic nanoassemblies and their multimodal imaging-guided tumor photothermal therapy10.1021/acsnano.6b03238 ↗
35. Development and regulation of exosome-based therapy products10.1002/wnan.1395 ↗
36. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer10.1016/j.biopha.2022.113690 ↗
37. "Triple-Punch" strategy exosome-mimetic nanovesicles for triple negative breast cancer therapy
38. Engineering macrophage exosome disguised biodegradable nanoplatform for enhanced sonodynamic therapy of glioblastoma
39. Doxorubicin-based hybrid compounds as potential anticancer agents: a review10.3390/molecules27144478 ↗
40. Doxorubicin-induced cardiotoxicity: causative factors and possible interventions10.1093/jpp/rgac063 ↗
41. Synergistic effects of temozolomide and doxorubicin in the treatment of glioblastoma multiforme: enhancing efficacy through combination therapy10.3390/molecules29040840 ↗
42. Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease10.1016/j.cca.2020.06.044 ↗
43. NLRP3 inflammasome activation and cell death10.1038/s41423-021-00740-6 ↗
44. Mechanism and regulation of pyroptosis-mediated in cancer cell death10.1016/j.cbi.2020.109052 ↗
45. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury10.1186/s13054-021-03775-3 ↗
46. Stem cell-derived exosomes prevent pyroptosis and repair ischemic muscle injury through a novel exosome/circHIPK3/FOXO3a pathway10.7150/thno.42259 ↗
47. Huc-MSCs-derived exosomes attenuate inflammatory pain by regulating microglia pyroptosis and autophagy via the miR-146a-5p/TRAF6 axis10.1186/s12951-022-01522-6 ↗
48. LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer10.1038/s41419-023-05840-x ↗
49. MicroRNA-122a aggravates intestinal ischemia/reperfusion injury by promoting pyroptosis via targeting EGFR-NLRP3 signaling pathway10.1016/j.lfs.2022.120863 ↗
50. Radiosensitizer EXO-miR-197-3p inhibits nasopharyngeal carcinoma progression and radioresistance by regulating the AKT/mTOR axis and HSPA5-mediated autophagy10.7150/ijbs.69934 ↗
51. Exosomes are involved in total body irradiation-induced intestinal injury in mice10.1038/s41401-021-00615-6 ↗
52. Engineering autologous cell-derived exosomes to boost melanoma-targeted radio-immunotherapy by Cascade cGAS-STING pathway activation